Janney Montgomery Scott LLC decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 20.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,991 shares of the life sciences company’s stock after selling 2,821 shares during the period. Janney Montgomery Scott LLC’s holdings in Illumina were worth $1,355,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Capital World Investors boosted its position in Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after buying an additional 124,323 shares during the last quarter. State Street Corp lifted its stake in shares of Illumina by 3.2% in the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after acquiring an additional 190,324 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after acquiring an additional 1,028,099 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Illumina by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after purchasing an additional 130,139 shares during the last quarter. Finally, Invesco Ltd. grew its stake in Illumina by 97.0% during the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after purchasing an additional 1,352,731 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.
Analyst Ratings Changes
ILMN has been the topic of several analyst reports. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $125.00 to $185.00 in a research report on Wednesday, June 10th. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Thursday, May 14th. Citigroup upped their price target on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $150.44.
Key Illumina News
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Illumina is being highlighted by market commentary as a biotech and life sciences momentum name, with analysts pointing to stronger earnings trends and sector leadership in healthcare. Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
- Positive Sentiment: Several articles frame ILMN as a strong momentum stock and note that it has outperformed recently, reinforcing bullish trading interest. Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know
- Positive Sentiment: Illumina announced new executive appointments, naming Michael Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, which may be viewed as a move to strengthen commercial execution and governance. Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Positive Sentiment: Illumina also announced it will report second-quarter 2026 results on July 30, keeping attention on upcoming fundamentals and guidance. Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Neutral Sentiment: Coverage also repeated bullish valuation and “mooning stock” themes, but these were largely commentary pieces rather than new company-specific developments. Illumina Stock Gains 43.7% in 2026: What’s Powering the Rally?
- Negative Sentiment: Short-interest data showed no meaningful bearish positioning change, so it does not currently add fresh downside pressure, though the report itself was unusual and offered little real signal. Illumina (ILMN) Stock May Be 27% Undervalued Following Strong Q1 Results
Illumina Stock Performance
Shares of NASDAQ ILMN traded down $3.56 during trading on Friday, reaching $190.20. The stock had a trading volume of 1,075,437 shares, compared to its average volume of 1,932,858. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The stock has a market cap of $28.78 billion, a PE ratio of 34.58, a P/E/G ratio of 3.56 and a beta of 1.47. Illumina, Inc. has a one year low of $88.00 and a one year high of $196.66. The firm’s 50 day moving average price is $161.31 and its two-hundred day moving average price is $141.50.
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Illumina news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the transaction, the director directly owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 1,003,769 shares of company stock worth $155,710,908. Corporate insiders own 2.90% of the company’s stock.
About Illumina
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Articles
- Five stocks we like better than Illumina
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
